Fractionated Stereotactic Radiosurgery With Concurrent Bevacizumab for Brain Metastases: A Phase I Dose-escalation Trial

This is an interventional treatment trial for Brain Neoplasm focused on measuring stereotactic radiosurgery,Bevacizumab Read More

Inclusion criteria

To be eligible for inclusion, patients must fulfill the following criteria:

1. Patients with a histologic diagnosis of non-hematopoietic malignancy and radiographic evidence of measurable brain metastases (1.5~3.5 cm).
2. The number of brain metastases receiving fractionated SRS: ≤3.
3. No evidence of leptomeningeal metastasis on gadolinium-enhanced MRI within 30 days prior registration.
4. Age ≥ 20 years.
5. Karnofsky Performance Status ≥ 60.
6. Life expectancy of ≥ 4 months.
7. Women of childbearing potential and male participants must practice adequate contraception.
8. Patients must be able to comply with the study protocol and follow-up schedules and provide study-specific informed consent.

Exclusion criteria Patients fulfill any of the following criteria will be excluded from this trial

1. Serum creatinine > 2.0 mg/dL within 30 days prior registration
2. Contraindication to magnetic resonance (MR) imaging such as implanted metal devices or foreign bodies, severe claustrophobia
3. Patients with evidence of bleeding diathesis or coagulopathy, international normalized ratio (INR) >1.5
4. Patients who require the use of warfarin sodium > 1 mg
5. Patients with active GI ulcers, GI bleeding, or active inflammatory bowel disease
6. Patients with clinically significant cardiac disease (e.g., uncontrolled hypertension [blood pressure of >160/90 mmHg on medication], history of myocardial infarction or unstable angina within 12 months of registration), New York Heart Association (NYHA) Class II or greater congestive heart failure, unstable symptomatic arrhythmia requiring medication (subjects with chronic atrial arrhythmia, i.e., atrial fibrillation or paroxysmal supraventricular tachycardia) are not eligible
7. Patients with a history of aneurysms, cerebrovascular accident (CVA) and arteriovenous malformations
8. Patients with arterial thromboembolic events, including transient ischemic attack (TIA), or clinically significant peripheral artery disease within 6 months of registration
9. Patients with serious, non-healing wound, ulcer, or current healing fracture
10. Patients with a history of any type of fistula (vesicovaginal, gastrointestinal, etc) or gastrointestinal perforation

11. Severe, active comorbidities which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and adverse events of the protocol, or limit compliance with study requirements, defined as follows:

    1. Uncontrolled active infection requiring intravenous antibiotics at the time of registration
    2. Transmural myocardial infarction ≤ 6 months prior to registration
    3. Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects
    4. Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration
    5. Uncontrolled psychiatric disorder
12. Will receive any other investigational agent or chemotherapy and/or target therapies during SRS
13. Women of childbearing potential and male participants who are sexually active and not willing/able to use medically acceptable forms of contraception; this exclusion is necessary because the radiation treatment involved in this study may be significantly teratogenic